Metadoxine extended-release - Alcobra

Drug Profile

Metadoxine extended-release - Alcobra

Alternative Names: MDX; Metadoxine sustained-release; MG-01CI; Pyridoxine pidolate; Pyridoxine pyrrolidone carboxylate

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alcobra
  • Class Drug withdrawal therapies; Imino acids; Picolines; Pyrrolidinones; Small molecules; Vitamins
  • Mechanism of Action Biogenic monoamine uptake modulators; Neurotransmitter stimulants; Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase II Fragile X syndrome

Most Recent Events

  • 28 Apr 2017 Alcobra has patents pending for metadoxine extended release and use of metadoxine for Attention-deficit hyperactivity disorder
  • 28 Apr 2017 Alcobra has patent protection for metadoxine extended release in USA, Israel and Canada
  • 28 Apr 2017 Alcobra has patent protection for the use of metadoxine for Attention-deficit hyperactivity disorder in Eurasia, Hong Kong and Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top